Zhao Yan Pharmaceutical (06127.HK) announced its mid-year performance, with a net profit of 60.932 million yuan, turning losses into profits year-on-year.

The Zhongyan New Drug (06127.HK) announced its mid-term performance for 2025 on the Zhitong Finance and Economics APP. The revenue is approximately 669 million yuan, a decrease of 21.3% year-on-year; the gross profit is about 105 million yuan, a decrease of 50.3% year-on-year; the net profit is 60.932 million yuan, turning losses into profits year-on-year; the earnings per share is 0.08 yuan.